CABA Stock Risk & Deep Value Analysis
Cabaletta Bio Inc
DVR Score
out of 10
What You Need to Know About CABA Stock
We analyzed Cabaletta Bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CABA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CABA Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Negative or mixed CABA-201 clinical data readouts (safety or efficacy)
- 📅
Clinical trial delays or increased patient dropout rates
- 📅
Need for additional capital raises leading to significant dilution
- 📅
Intensified competition from other autoimmune cell therapy approaches
- 📅
Unexpected regulatory hurdles or adverse events during trials
Unlock CABA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Cabaletta Bio is a high-conviction speculative play on the transformative potential of precision CAR-T cell therapy for severe autoimmune diseases. With CABA-201 showing encouraging early clinical data, a differentiated mechanism of action, and sufficient funding runway, the company is strategically positioned to capture a significant portion of a multi-billion-dollar market. Further positive clinical readouts are expected to de-risk the asset, unlocking substantial shareholder value and offering significant upside potential within a 3-5 year horizon.
Is CABA Stock Undervalued?
Unlock the full AI analysis for CABA
Get the complete DVR score, risk analysis, and more
CABA Price Targets & Strategy
12-Month Target
$11.50
Bull Case
$28.00
Bear Case
$1.50
Entry Strategy
Consider dollar-cost averaging on dips below $4.00, especially if accompanied by positive clinical updates or expanded patient enrollment news. Avoid chasing sharp spikes.
Exit Strategy
Take initial profits (e.g., 25-30%) at $10-$12, then scale out additional portions at $20+ if clinical data continues to de-risk the asset. Set a trailing stop-loss, or a hard stop-loss if CABA-201 data disappoints, below $2.50.
Portfolio Allocation
10-15% for aggressive risk tolerance; 3-7% for moderate risk tolerance, acknowledging the speculative nature.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does CABA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat, primarily derived from its proprietary CAR T platform and specific antigen-targeting approach, will become more durable as CABA-201 progresses through clinical trials, demonstrating sustained efficacy and a favorable safety profile. Successful regulatory approvals and manufacturing expertise will further strengthen it.
Moat Erosion Risks
- •Clinical trial failures or significant safety concerns with CABA-201
- •Emergence of superior or more cost-effective treatments from competitors
- •Intellectual property challenges or expiration of key patents
- •Difficulties in manufacturing scale-up or cost reduction
CABA Competitive Moat Analysis
Sign up to see competitive advantages
CABA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Positive
Insider Activity (Form 4)
No significant insider buying or selling reported since late 2025; activity likely aligns with pre-scheduled plans.
Options Flow
Low liquidity in options market; limited unusual activity detected, indicating retail focus on direct equity.
Earnings Intelligence
Next Earnings
Estimated early-May 2026
Surprise Probability
Low
Historical Earnings Pattern
Stock price is highly volatile around clinical trial updates and presentations, rather than financial earnings reports. Significant reactions often occur following efficacy or safety data releases.
Key Metrics to Watch
Competitive Position
Top Competitor
KYTX
Market Share Trend
N/A (pre-revenue, pre-commercialization)
Valuation vs Peers
Cabaletta trades at a significant discount to peers with late-stage assets but may trade at a premium to early-stage companies due to differentiated platform and promising early data. Valuation is primarily driven by future pipeline success.
Competitive Advantages
- •Precision-targeted CAR-T cell therapy specifically for autoimmune diseases
- •Antigen-specific B-cell depletion approach (CABA-201)
- •Experienced leadership team with deep expertise in immunology and cell therapy development
- •Strong intellectual property protecting its platform and lead assets
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CABA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Release (Estimated early-May 2026)
- •Additional CABA-201 Phase 1/2 data updates from ongoing Myasthenia Gravis (MG) and potentially Myositis (MMP) cohorts (Q2-Q3 2026)
- •Presentations at major medical conferences (e.g., EULAR, ACR) showcasing CABA-201 data (Q2-Q3 2026)
Medium-Term (6-18 months)
- •Potential initiation of CABA-201 Phase 2 expansion cohorts or new indications (Late 2026 / Early 2027)
- •Update on manufacturing process scale-up and optimization (2027)
- •Preclinical pipeline updates and potential new IND filings (2027)
Long-Term (18+ months)
- •CABA-201 progression into pivotal Phase 3 trials (2028+)
- •Strategic partnerships with larger pharmaceutical companies for late-stage development or commercialization (2028+)
- •Establishment of CABA-201 as a market leader in targeted autoimmune cell therapy
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CABA?
- ✓
Consistent positive efficacy and safety data from CABA-201 Phase 1/2 trials (especially durability and low/no CAR-T toxicities)
- ✓
Successful expansion into new autoimmune indications or patient populations for CABA-201
- ✓
Maintenance of a strong cash position without excessive dilution through non-equity funding or partnerships
Bull Case Analysis
See what could go right with Premium
Competing with CABA
See how Cabaletta Bio Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Cabaletta Bio Inc CABA | — | 7.9 | — | — | — | — |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Cabaletta Bio Inc (CABA)?
As of March 17, 2026, Cabaletta Bio Inc has a DVR Score of 7.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for CABA stock?
Our analysis rates Cabaletta Bio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the CABA DVR analysis updated?
Our AI-powered analysis of Cabaletta Bio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 17, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CABA (Cabaletta Bio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.